# Vicarious Surgical Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Vicarious Surgical Inc.). ## Overview Vicarious Surgical Inc. is a U.S.-based medical technology company developing a single-port robotic surgical system for minimally invasive procedures. Its platform combines miniaturized robotics, sensing, computer science, and 3D visualization to support surgeons performing operations through a small access point. ## Products & services • Vicarious Surgical System • Single-port robotic surgery platform • Minimally invasive surgical technology • 3D visualization and sensing system • Surgical robotics development and testing - **Robotic surgical systems** (100%) — Single-port robotic platforms designed to support minimally invasive surgery. - Vicarious Surgical System - Single-port robotic surgery platform - Minimally invasive surgical technology - 3D visualization and sensing system - Surgical robotics development and testing ## Customers The company’s intended customers are hospitals and ambulatory surgery centers that would purchase robotic systems for surgical procedures. Its first planned clinical application is ventral hernia repair, with broader use cases in abdominal and gynecological surgery over time. - **Hospitals** (primary) — Large acute-care hospitals that would buy the system for minimally invasive surgical procedures and operating-room capability. - **Ambulatory surgery centers** (primary) — Outpatient surgical facilities that would use the platform for selected procedures where efficiency and access matter. - **Surgeons and clinical users** (secondary) — Physicians and surgical teams who influence adoption based on usability, precision, and workflow benefits. - **International healthcare providers** (emerging) — Non-U.S. hospitals and surgical centers that may adopt the system after regulatory approvals and market entry. - Hospitals evaluating robotic systems for minimally invasive surgery - Ambulatory surgery centers seeking efficient surgical platforms - Surgeons and clinical teams using the system in operating rooms - Healthcare organizations focused on procedural precision and ergonomics - Future international buyers as commercialization expands ## Geography Vicarious Surgical is headquartered and manufactures in Waltham, Massachusetts, in the United States. The company currently serves a U.S. development and regulatory base, while also expecting future international commercialization and clinical activity. - Headquartered in Waltham, Massachusetts - Manufacturing capabilities located at the U.S. headquarters - Primary regulatory and development focus in the United States - Future sales expected to expand internationally - International clinical trials and product studies may add complexity ## Strategy The company is focused on advancing its single-port robotic surgery platform toward regulatory authorization and eventual commercialization. Its strategy centers on proving clinical utility, building surgeon and hospital adoption, and expanding the platform across additional procedures and geographies. - **Obtain regulatory authorization** (short-term) — Commercial sales depend on FDA and other regulatory approvals. - **Prove clinical and economic value** (medium-term) — Hospitals and surgeons need evidence of precision, efficiency, and outcomes before adoption. - **Expand procedure coverage** (medium-term) — A broader indication set increases the addressable market and long-term adoption potential. - **Prepare for commercial scale-up** (medium-term) — Manufacturing, supply chain, and sales infrastructure must support future system deployment. - Advance the Vicarious Surgical System toward FDA authorization - Demonstrate clinical value in ventral hernia repair first - Expand from one procedure into broader abdominal surgery use - Build hospital and surgeon awareness of robotic-assisted surgery - Develop manufacturing and supplier capabilities for future scale ## Risks The business depends on successful product development, regulatory approval, and eventual market acceptance of a complex surgical robot. It also faces execution risk from product reliability, supplier concentration, competition from established surgical robotics companies, and the need to maintain access to public markets and capital. - **Regulatory approval risk** [critical] — The company cannot generate product revenue until the system receives FDA authorization and other approvals. - **Product performance and liability risk** [high] — A surgical robot must work reliably in complex procedures, and defects could cause patient harm, recalls, or reputational damage. - **Competitive risk** [high] — Established players such as Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, and CMR Surgical compete in robotic surgery. - **Supplier concentration risk** [medium] — Some components are sole-sourced or single-sourced, which can disrupt assembly and testing if supply is interrupted. - **Going-concern and capital access risk** [critical] — The company disclosed substantial doubt about its ability to continue as a going concern, reflecting dependence on external funding. - **NYSE listing compliance risk** [high] — The company received notice that it was no longer in compliance with minimum market capitalization standards. - No revenue yet; commercialization depends on regulatory authorization - Product reliability failures could delay adoption or trigger recalls - Competition from larger surgical robotics companies is intense - Single-source suppliers can create component and manufacturing risk - Going-concern and listing compliance risks remain material ## Accounting The company is pre-revenue, so reported results are driven mainly by research and development, professional services, and other operating expenses rather than sales recognition. A key accounting judgment is the fair value measurement of warrant liabilities, which can create earnings volatility through remeasurement gains or losses. - **Warrant liabilities** — Can create non-cash gains or losses in the statement of operations - **Pre-revenue expense recognition** — Makes period-to-period comparisons sensitive to spending cadence - **Fair value of investments** — Can influence other income and cash management disclosures - **Going-concern assessment** — Important for interpreting liquidity and financial statement assumptions - No revenue recognition yet because the product is not commercialized - Warrant liabilities are remeasured at fair value each period - Black-Scholes inputs affect private warrant valuation - Available-for-sale investments affect interest income and cash balances - Pre-revenue expense mix is dominated by R&D and professional services --- *Last updated: 2026-04-29T05:08:02.003336+00:00*